Format

Send to

Choose Destination
Eur Heart J Suppl. 2017 May;19(Suppl D):D370-D379. doi: 10.1093/eurheartj/sux019. Epub 2017 May 2.

ANMCO/AIOM/AICO Consensus Document on clinical and management pathways of cardio-oncology: executive summary.

Author information

1
Cardiology Department, Ospedale San Martino, S.C. Cardiologia, Ospedale San Martino, Azienda ULSS 1, Viale Europa 22, 32100 Belluno, Italy.
2
Cardiology Department, Ospedale Garibaldi-Nesima, Azienda di Rilievo Nazionale e Alta Specializzazione "Garibaldi", Catania, Italy.
3
Cardiovascular Center, Azienda Sanitaria Universitaria Integrata, Trieste, Italy.
4
Cardiology Department, Istituto Nazionale Tumori, IRCCS Fondazione "G. Pascale", Napoli, Italy.
5
CCU- Cardiology Department, Ospedale S. Antonio Abate, Erice, TP, Italy.
6
Cardiology Unit, A.O. San Camillo-Forlanini, Roma, Italy.
7
Cardiology Unit, A.O. Santa Maria, Terni, Italy.
8
CCU-Cardiolgoy Department, Ospedale San Paolo, Bari, Italy.
9
Cardiology Unit, Ospedale Nuovo Regina Margherita, Roma, Italy.
10
Cardiology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.
11
Cardiology Unit, Ospedale Mauriziano, Torino, Italy.
12
Cardiology Department, Ospedale Santo Spirito, Roma, Italy.
13
Oncology Department, Ospedale Sacro Cuore Don Calabria, Negrar, VR, Italy.

Abstract

Cardiovascular disease and cancer are leading causes of death. Both diseases share the same risk factors and, having the highest incidence and prevalence in the elderly, they often coexist in the same individual. Furthermore, the enhanced survival of cancer patients registered in the last decades and linked to early diagnosis and improvement of care, not infrequently exposes them to the appearance of ominous cardiovascular complications due to the deleterious effects of cancer treatment on the heart and circulatory system. The above considerations have led to the development of a new branch of clinical cardiology based on the principles of multidisciplinary collaboration between cardiologists and oncologists: Cardio-oncology, which aims to find solutions to the prevention, monitoring, diagnosis and treatment of heart damage induced by cancer care in order to pursue, in the individual patient, the best possible care for cancer while minimizing the risk of cardiac toxicity. In this consensus document we provide practical recommendations on how to assess, monitor, treat and supervise the candidate or patient treated with potentially cardiotoxic cancer therapy in order to treat cancer and protect the heart at all stages of the oncological disease. Cardiovascular diseases and cancer often share the same risk factors and can coexist in the same individual. Such possibility is amplified by the deleterious effects of cancer treatment on the heart. The above considerations have led to the development of a new branch of clinical cardiology, based on multidisciplinary collaboration between cardiologist and oncologist: the cardio-oncology. It aims to prevent, monitor, and treat heart damages induced by cancer therapies in order to achieve the most effective cancer treatment, while minimizing the risk of cardiac toxicity. In this paper, we provide practical recommendations on how to assess, monitor, treat and supervise patients treated with potential cardiotoxic cancer therapies.

KEYWORDS:

Cancer; Cardio-oncology; Cardiotoxicity; Cardiovascular disease

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center